

Correction to “Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators”

The above article [Her L and Zhu H-J (2020) *Drug Metab Dispos*, **48**: 230-244; DOI: <https://doi.org/10.1124/dmd.119.089680>] was published with an error introduced by the compositor. In Table 1, the heading for the first column was incorrectly given as “ACE (Adrenocortical Extract) Inhibitors.” It should be “ACE (Angiotensin-Converting Enzyme) Inhibitors.” The corrected Table 1 is provided below.

The PDF and HTML versions of the article have been corrected.

The compositor apologizes for any inconvenience caused by this error.

TABLE 1
List of CES1 substrates

ACE (Adrenocortical Extract) Inhibitors	CNS (Central Nervous System) agents	Antihyperlipidemia agents
Enalapril ^a	Methylphenidate	Clofibrate
Imidapril ^a	Cocaine	Fenofibrate
Benzapril ^a	Heroin	
Quinapril ^a	Meperidine	Adrenal glucocorticoid
Ramipril ^a	Flumazenil	Ciclesonide ^a
Trandolapril ^a	Rufinamide	
Antiviral agents	Anticancer agents	Chemical warfare agents
Oseltamivir ^a	Capecitabine ^a	Sarin
Sofosbuvir ^a	Irinotecan ^a	Soman
Tenofovir alafenamide ^a	Telotristat etiprate ^a	Tabun
Endogenous Compounds	Antiplatelets/anticoagulants	Pesticides
Cholesterol	Clopidogrel	Trans-permethrin
Fatty acid ethyl esters	Dabigatran ^a	Para-nitrophenyl valerate
Angiotensin receptor-neprilysin inhibitor (ARNi)	Immunosuppressive agents	Others
Sacubitril ^a	Mycophenolate mofetil ^a	Dimethyl fumarate ^a
		Oxybutynin

^aProdrugs that need CES1 activation.